Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyNeuro-OncologyRegional therapyVisceral SurgeryDiseaseBile Duct CarcinomaBreast CancerEndometrial CancerFallopian Tube CarcinomaGastric CancerOvarian TumorPancreatic CancerPeritoneal Carcinomatosis, SecondaryTumor Biomarker DefinedSubgroupBRAF V600-MutationBRCA mutationClear Cell CancerEpCAM positiveepithelialFolate receptor alpha positiveMalignant Germ Cell Tumor of the Ovaryserous, borderlineserous, low-gradeICD10C16.-C16.0C24.-C24.0C24.1C24.8C24.9C25.-C50.-C54.1C56C57.0C78.6MeSHBile Duct NeoplasmsBiliary TractBiliary Tract NeoplasmsBreast NeoplasmsCarcinoma, Ovarian EpithelialCommon Bile Duct NeoplasmsEndometrial NeoplasmsFallopian Tube NeoplasmsNeoplasmsNeoplasms, Germ Cell and EmbryonalOvarian NeoplasmsPancreatic NeoplasmsPeritoneal NeoplasmsStomach NeoplasmsSequenceBEVA10/CRBP5/PGLDX30, ovarian Ca (PID2187) -|- BEVA15, maint. (PID1430)BEVA15/PACL175/CRBP5, ovarian Ca (PID1429) -|- BEVA15, maint.. (PID1430)MoST-CIRCUIT: NIVO3/IPIL1, Ovarian Ca and Endometrial Ca (PID3009) -|- NIVO480, Erh. (PID3010)PACL175/CRBP6/BEVA15, ovarian Ca C1 (PID498) -|- C2+ (PID499)Antineoplastic therapySubstanceBevacizumabBinimetinibCapecitabineCarboplatinCatumaxomabCisplatinCyclophosphamideDabrafenibDocetaxelDoxorubicin pegylated liposomalEtoposideFluorouracilFolinic acidGemcitabineIpilimumabIrinotecanLetrozoleMirvetuximab SoravtansinNab-paclitaxelNaCl 0.9%NiraparibNivolumabOlaparibOxaliplatinPaclitaxelPazopanibPembrolizumabRucaparibTopotecanTrabectedinTrametinibTreosulfanSubstanceBevacizumabBinimetinibCapecitabineCarboplatinCatumaxomabCisplatinCyclophosphamideDabrafenibDocetaxelDoxorubicin pegylated liposomalEtoposideFluorouracilFolinic acidGemcitabineIpilimumabIrinotecanLetrozoleMirvetuximab SoravtansinNab-paclitaxelNaCl 0.9%NiraparibNivolumabOlaparibOxaliplatinPaclitaxelPazopanibPembrolizumabRucaparibTopotecanTrabectedinTrametinibTreosulfanSubstanceBevacizumabBinimetinibCapecitabineCarboplatinCatumaxomabCisplatinCyclophosphamideDabrafenibDocetaxelDoxorubicin pegylated liposomalEtoposideFluorouracilFolinic acidGemcitabineIpilimumabIrinotecanLetrozoleMirvetuximab SoravtansinNab-paclitaxelNaCl 0.9%NiraparibNivolumabOlaparibOxaliplatinPaclitaxelPazopanibPembrolizumabRucaparibTopotecanTrabectedinTrametinibTreosulfanSubstanceBevacizumabBinimetinibCapecitabineCarboplatinCatumaxomabCisplatinCyclophosphamideDabrafenibDocetaxelDoxorubicin pegylated liposomalEtoposideFluorouracilFolinic acidGemcitabineIpilimumabIrinotecanLetrozoleMirvetuximab SoravtansinNab-paclitaxelNaCl 0.9%NiraparibNivolumabOlaparibOxaliplatinPaclitaxelPazopanibPembrolizumabRucaparibTopotecanTrabectedinTrametinibTreosulfanNo. Substances123 RadiotherapySupportive therapySubstanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHyaluronic acidMagnesiumMagnesium sulfateNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePyridoxineSodium ThiosulfateSubstanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHyaluronic acidMagnesiumMagnesium sulfateNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePyridoxineSodium ThiosulfateSubstanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHyaluronic acidMagnesiumMagnesium sulfateNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePyridoxineSodium ThiosulfateSubstanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHyaluronic acidMagnesiumMagnesium sulfateNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePyridoxineSodium ThiosulfateNo. Substances1234567Protocol classificationTherapy classificationalternativecurrent standardstudy analogIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleThird line Therapy phaseInductionintraoperativMaintenanceTherapy intentioncurativecurative or palliativepalliativeRisksAllergic ReactionAlopeciaAnemia Hb below 8g/dlArthalgiaAstheniaBleedingCardiotoxicityColitisConstipationDiarrheaDyspneaEdemaElectrolyte DisturbanceEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaGastrointestinal ToxicityHand-Foot SyndromeHeadacheHematotoxicityHemorrhageHepatotoxicityHyperglycemiaHypertensionHypomagnesemiaHyponatremiaHypophysitisHypothyroidismIncrease Alkaline PhosphataseIncrease AminotransferasesIncrease Creatinine PhosphokinaseInfectionsKeratopathyLeukopeniaLymphopeniaMucositisMyalgiasMyocarditisNephrotoxicityNeuropathyNeurotoxicityNeutropeniaOral MucositisPainPancreatitisProteinuriaPyrexiaRashRenal FailureThrombocytopenia below 50 000/µlThromboembolic EventVisual DisturbancesVomiting only studiesPublicationAuthorAghajanian CBarber ELBell JBurger RAColeman RColombo NConteduca VDu Bois AFerrandina GFriedlander MGao BGershenson DMGonzález Martín A Gordon ANGrisham RNHandolias DHeiss MMKatsumata NMarkman MMatulonis UAMirza MMonk BJMoore K / Pujade-Lauraine EMorgan RDMutch DGPapadimitriou CAPerren TJPfisterer JPignata SPujade-Lauraine ERaspagliesi FRay-Coquard I Salama AKSSehouli CSehouli JSugiyama T Tanyi JTillmanns Tvan Driel WVasey PVasey PAWilliams SDZsiros RDiseaseDysgerminom, Stadium IB-III, nach kompletter Resektion, bei Patientinnen, die keine hohe Toxizität tolerieren könnenFortgeschrittenes oder metastasiertes Ovarialkarzinom, Rezidivtherapie, ECOG 0-2Fortgeschrittenes oder metastasiertes Ovarialkarzinom, Rezidivtherapie, platinresistent, ECOG 0-1frühes Ovarial-Ca, Stadium I und II, ErstlinieKlarzelliges Ovarialkarzinom, max. 6 Wochen nach der Operation, ECOG 0-1Lokal fortgeschrittene oder metastasierte Karzinome, BRAF V600E mutiert, Progress nach der Erstlinientherapie, ECOG 0-2Neudiagnostiziertes Ovarial-Ca, Eileiter-Ca oder Peritoneal-Ca, Stadium III mit neoadjuvanter Therapie, ECOG 0-2neudiagnostiziertes Ovarial-Ca, Stadium III/IV, Erstlinienbehandlung mit Platin-/Taxan-/Bevacizumabtherapie, ECOG 0-1Ovarial-Ca, FIGO Ic–IV, postoperativ, ECOG 0-2, keine vorausgegangene Chemotherapie oder RadiatioOvarial-Ca, fortgeschritten, nach Debulking-OP, ECOG 0-2Ovarial-Ca, inkompl. resekt. Stadium III oder jedes Stadium IV, ErstlinieOvarial-Ca, nach OP, high-risk early stage oder fortgeschritten, ECOG 0-2Ovarial-Ca, Rezidiv, platinsensitiv, Zweitlinie, BRCA Mutation, ECOG 0-1Ovarial-Ca, Rezidiv innerhalb von 6 Monaten nach platinbasierter ErstlinieOvarial-Ca, Rezidiv innerhalb von 6 Monaten nach platinbasierter Erstlinie/ZweitlinieOvarial-Ca, Rezidiv nach oder refraktär nach/unter platinbasierter Erstlinie.Ovarial-Ca, Rezidiv nach oder refraktär nach/unter platinbasierter Erstlinie innerhalb von 12 Monaten, ECOG 0-2Ovarial-Ca fortgeschritten, Stadium II-IVOvarial-Ca Rezidiv, mehr als 6 Monate nach Komplettierung der Platinum-basierten Erst- oder Zweitlinie (Platinum-sensitives Rez.), Taxan-Vorhterapie, ECOG 0-2Ovarial-Ca Rezidiv, mehr als 6 Monate nach Komplettierung der Platinum-basierten Erstlinie (Platinum-sensitives Rez.), ECOG 0-1Ovarial-Ca Rezidiv, mehr als 6 Monate nach Komplettierung der Platinum-basierten Erstlinie (Platinum-sensitives Rez.), ECOG 0-2Ovarial-Ca Rezidiv, nach Platinum-basierter Erstlinie, Progress innerhalb und nach mehr als 6 Monaten (Platinumresistent und -sensibel; Platinumrefraktäre Patienten waren ausgeschlossen), ECOG 0-2Ovarial- oder Endomteriumkarzinom, klarzellig, lokal fortgeschritten, inoperabel, ECOG 0-1Ovarialkarzinom, Erstlinie, ECOG 0-2Ovarialkarzinom, Peritonealkarzinom, Karzinom der Eileiter, Rezidivtherapie, >6 Monate Erstlinie mit Platin, ECOG 0-2Ovarialkarzinom, Rezidiv nach oder refraktär nach/unter platinbasierter ErstlinieOvarialkarzinom, Rezidiv nach oder refraktär nach/unter platinbasierter Erstlinie, ECOG 0-2Ovarialkarzinom, serös, low-grade oder Borderline-Tumor, Progress nach platinhaltiger ChemotherapieOvarialkarzinom, Stadium IC-IV, ECOG 0-2Peritonealkarzinose, sekundär, EpCAM positivplatinsensitives Ovarial-Ca oder primäre Peritonealkarzinose, Drittlinie, ECOG 0-1Rezidiv. Ovarial-Ca, mind. 6 Mo krankheitsfreies Intervall nach letzter Cisplatingabe und Ansprechen auf mind. 3 Zyklen Cisplatin in der Erstlinie, ECOG 0-2rezidivierendes, platinsensitives Ovarialkarzinom, Rezidivtherapie, ECOG 0-1rezidivierendes Ovarialkarzinom, Drittlinie, Karnofsky > 70%rezidivierendes Ovarialkarzinom, fallopian tube or primary peritoneal cancer, ECOG 0-1rezidivierendes Ovarialkarzinom, nach platinbasierter Erstlinie, ECOG 0-2Rezidiviertes fortgeschrittenes oder metastasiertes OvarialkarzinomRezidiviertes fortgeschrittenes oder metastasiertes Ovarialkarzinom, nach platinhaltiger Therapie, ECOG 0-1Rezidiviertes fortgeschrittenes oder metastasiertes Ovarialkarzinom, platinresistentRezidiviertes fortgeschrittenes oder metastasiertes Ovarialkarzinom, platinresistent, FR-alpha positiv, ECOG 0-1Rezidiviertes fortgeschrittenes oder metastasiertes Ovarialkarzinom, Zweitlinierezidiviertes Ovarialkarzinom, Eileiterkarzinom oder primäres Peritonealkarzinom, Cisplatin-sensitiv, Drittlinie, ECOG 0-1rezidiviertes Ovarialkarzinom, nach platinbasierter Erstlinie, ECOG 0-2wiederkehrendes oder fortschreitendes Ovarial-Ca/Peritoneal-Ca, Stadium I-IV, nach Platintherapie, ECOG 0-1OriginAGO-OVAR, NCIC CTG, EORTC GCGArbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group and Gynaecologic Oncology Center, Kiel, Germany, AGO-OVAR 2.21/ENGOT-ov 18 InvestigatorsBeatson Oncology Centre, Western Infirmary, Glasgow, UKCentre Léon Bérard, France, PAOLA-1 TrialsCharité University Medical Center and Center for Clinical Research, Berlin, NOGGOCologne-Merheim Medical Center, University of Witten-Herdecke, Cologne, GermanyDana-Farber Cancer Institute, Boston, MA, SORAYA StudyDepartment of Clinical Therapeutics, Alexandra Hospital, Athens University School of Medicine, AthensDepartment of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New YorkDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas, Houston, USA, GOG-0213Department of Gynecology, Netherlands Cancer Institute, AmsterdamDepartment of Medical Oncology, Blacktown and Westmead Hospitals, Sydney, Australia, MoST-CIRCUIT trialDepartment of Medical Oncology, Glasgow, U.K.Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas, USADepartment of Oncology, Catholic University, Campobasso, ItalienDepartment of Oncology, Rigshospitalet–Copenhagen University Hospital, ENGOT-OV16/NOVA InvestigatorsDuke University, Durham, NC, NCI-MATCH Trial Subprotocol HEuropean Institute of Oncology, Milan, ItalyGCIG, GINECO, AGO, NSGO, ANZGOG, NCIC-CTG, EORTC, MITO, MaNGO; CALYPSO StudieGynecology and Gynecologic Oncology, Charité University Medicine Campus Virchow, Berlin, Germany, NOGGOHorst Schmidt Klinik, Wiesbaden, DeutschlandIndiana University Cancer Center, Indianapolis, USAIstituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione G Pascale, IRCCS, Napoli, Italy, MITO-7 trialIstituto Nazionale per lo Studio e la Cura dei Tumori, MilanoIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, ItalyJapanese Gynecologic Oncology Group, JGOG 3016 StudieManchester Cancer Research Centre, University of Manchester, UKMD Anderson Cancer Center Spain, Madrid, Spain, ICON7 investigatorsMemorial Sloan Kettering Cancer Center, New York, USA; OCEANS StudieMemorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, New York, 3 MILO/ENGOT-ov11 StudyPrince of Wales Hospital, Randwick, Sydney, AustraliaRoyal Women's Hospital, Melbourne, Victoria, AustraliaStevenson Cancer Center, University of Oklahoma, SOLO2/ENGOT-Ov21 investigatorsThe Gynecologic Oncology GroupThe Gynecologic Oncology Group; GOG-0218 StudieThe ICON7 Investigators, ICON7 StudieThe Jikei University School of Medicine, Tokyo, Japan, JGOG3017/GCIG TrialThe Nordic Society of Gynecological Oncology (NSGO) and Rigshospitalet, Copenhagen, Denmark, ENGOT-OV24 / AVANOVA1The Texas Ocology Professional Association, Dallas Texas, USAThe University of Texas MD Anderson Cancer Center, ARIEL3 StudieThe University of Texas MD Anderson Cancer Center, Houston, USA, GOG 281/LOGS trialThe West Clinic, Memphis, USAUniversite Paris Descartes, Hopitaux Universitaires Paris Centre, AURELIAUniversity Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USAUniversity of California at Irvine and UCI Medical Center, Orange, CA, USAWashington University School of Medicine, USAProtocols in Revision 55 protocols foundBevacizumab 10 / Carboplatin 5 / Doxorubicin Pegylated Liposomal 30, Ovarian Ca. (PID2187 V1.0)Bevacizumab 10 / Cyclophosphamide 50, Ovarian Carcinoma (PID2832 V1.0)Bevacizumab 15 / Gemcitabine 1000 / Carboplatin 4, Ovarian ca (PID126 V1.1)Bevacizumab 15 / Paclitaxel 175 / Carboplatin 5, Ovarian ca (PID1429 V1.0)Bevacizumab 15, Ovarian Carcinoma (PID495 V1.3)Bevacizumab 15, Ovarian Carcinoma, maintenance. (PID1430 V1.1)Bevacizumab 7.5, Ovarian Carcinoma (PID501 V1.0)Binimetinib 45, Ovarian Ca (PID2671 V1.0)Capecitabine 1250, Ovarian Carcinoma (PID2191 V1.0)Carboplatin 5, Ovarian ca (PID1332 V1.0)Carboplatin 6 / Etoposide 120, Ovarian Tumor (PID2188 V1.0)Carboplatin 7, Ovarian ca (PID1428 V1.0)Catumaxomab (10/20/50/150), Peritoneal Carcinomatosis, Secondary (PID3037 V1.0)Cisplatin 35 / Gemcitabine 1000, Ovarian Carcinoma (PID2190 V1.0)Cyclophosphamide 150, Ovarian Carcinoma (PID2192 V1.0)Dabrafenib 150 / Trametinib 2, Tumor Biomarker Defined (PID2197 V1.0)Docetaxel 75 / Carboplatin 5, Ovarian ca (PID1421 V1.1)Gemcitabine 1000 / Carboplatin 4, Ovarian ca (PID493 V1.2)Gemcitabine 1000, Ovarian Carcinoma (PID504 V1.2)Gemcitabine 1000, Ovarian ca, variant 1 (PID505 V1.2)GemOx - Gemcitabine 1000 / Oxaliplatin 130, Ovarian Carcinoma (PID2195 V1.0)HIPEC - Cisplatin 100, Ovarian ca (PID108 V2.1)Irinotecan 60 / Cisplatin 60, Ovarian Carcinoma (PID2194 V1.0)Letrozole 2.5, Ovarian Carcinoma (PID2200 V1.0)Mirvetuximab soravtansine 6, Ovarian Carcinoma (PID2606 V1.0)Nab-Paclitaxel 100 / Bevacizumab 10, Ovarian ca (PID900 V1.0)Niraparib 300 / Bevacizumab 15, Ovarian ca, maintenance (PID487 V1.1)Niraparib 300, ovarian carcinoma, maintenance (PID477 V1.1)Nivolumab 3 / Ipilimumab 1 - Nivolumab 480, Ovarian Carcinoma and Endometrial Cancer, maintenance (PID3010 V1.0)Nivolumab 3 / Ipilimumab 1, Ovarian Carcinoma and Endometrial Cancer (PID3009 V1.0)Olaparib 300 / Bevacizumab 15, Ovarian ca, maintenance (PID1351 V1.0)Olaparib 300, Ovarian ca, maintenance (PID531 V2.0)Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 600, Ovarian Carcinoma. (PID2196 V1.0)Paclitaxel 175 / Carboplatin 5 / Bevacizumab 7.5, Ovarian Carcinoma (PID500 V1.1)Paclitaxel 175 / Carboplatin 5, Ovarian ca (PID497 V1.2)Paclitaxel 175 / Carboplatin 6 / Bevacizumab 15, Ovarian Carcinoma cycle 1 (PID498 V1.1)Paclitaxel 175 / Carboplatin 6 / Bevacizumab 15, Ovarian Carcinoma cycle 2+ (PID499 V1.2)Paclitaxel 175 / Carboplatin 7.5, Ovarian ca, adjuvant (PID1335 V1.2)Paclitaxel 60 / Carboplatin 2, Ovarian Carcinoma (PID2429 V1.0)Paclitaxel 80 / Bevacizumab 10, Ovarian ca (PID1366 V1.1)Paclitaxel 80 / Carboplatin 6, Ovarian ca (PID91 V1.2)Paclitaxel 80, Ovarian Carcinoma (PID508 V1.1)Pazopanib 800, Ovarian Carcinoma (PID2193 V1.0)Pegylated liposomal Doxorubicin 30 / Carboplatin 5, Ovarian Ca (PID494 V1.1)Pegylated Liposomal Doxorubicin 30 / Trabectedin 1,1, Ovarian Carcinoma (PID496 V1.0)Pegylated liposomal Doxorubicin 40 / Bevacizumab 10, Ovarian ca (PID1367 V1.0)Pegylated Liposomal Doxorubicin 40, Ovarian ca (PID913 V1.0)Pegylated Liposomal Doxorubicin 50, Ovarian Carcinoma (PID502 V1.0)Pembrolizumab 200 / Bevacizumab 15 / Cyclophosphamide 50, Ovarian ca (PID1109 V1.1)Rucaparib 600, Ovarian ca, maintenance (PID1501 V1.1)Topotecan 1.25 / Bevacizumab 15, Ovarian ca (PID1368 V1.0)Topotecan 1.5, Ovarian Carcinoma (PID503 V2.0)Topotecan 4, Ovarian ca (PID860 V1.0)Trametinib 2, ovarian cancer (PID2670 V1.0)Treosulfan 7, Ovarian ca (PID863 V1.1)
